Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models.

Genome Biol · 2016 · PMC5031330 · PMID 27654937

Europe PMC DOI

hedged sentence

0.0300

closest p · 0.6× alpha

0.0300

boldest claim

The sentences

nominally significantP = 0.03actually significant

These associations were also identified as nominally significant in CTRP, whereby GO process “Growth” is associated with PC2 ( P = 0.03) and “Regulation of Apoptosis” is associated with PC3 ( P = 0.01) and PC5 ( P = 0.01).

also in 4,850 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.